Inventor · Mahwah, NJ, US

Daniel P. Rossignol

17Patents
10h-index
15Co-inventors
65Inventor score

Filing activity: Aug 25, 1992 → Jun 13, 2011

Most-cited inventions

PatentTitleAreaCited byStatus
US5530113A Anti-endotoxin compounds Chemistry; Metallurgy 42 Expired
US5756718A Anti-endotoxin compounds Chemistry; Metallurgy 32 Expired
US6290973A Immunological adjuvant compounds, compositions, and methods of use thereof Human Necessities 29 Expired
US5681824A Substituted liposaccharides useful in the treatment and prevention of endotoxemia Chemistry; Metallurgy 24 Expired
US5612476A Anti-endotoxin compounds Chemistry; Metallurgy 23 Expired
US5843918A Anti-endotoxin compounds Chemistry; Metallurgy 22 Expired
US5952309A Method for treating alcoholic liver disease Human Necessities 22 Expired
US6683063B2 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs Chemistry; Metallurgy 18 Expired
US6184366A Substituted liposaccharides useful in the treatment and prevention of endotoxemia Chemistry; Metallurgy 12 Expired
US7348316B2 Use of an anti-endotoxin drug in the prevention and treatment of disease Human Necessities 11 Expired
US5750664A Substituted liposaccharides useful in the treatment and prevention of endotoxemia Chemistry; Metallurgy 8 Expired
US5935938A Substituted liposaccharides useful in the treatment and prevention of endotoxemia Chemistry; Metallurgy 7 Expired
US6417172B1 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs Chemistry; Metallurgy 6 Expired
US7737129B2 Substituted liposaccharides useful in the treatment and prevention of endotoxemia Chemistry; Metallurgy 2 Active
US7976852B2 Compositions and methods for cancer immunotherapy Human Necessities 1 Expired
US7994154B2 Substituted liposaccharides useful in the treatment and prevention of endotoxemia Chemistry; Metallurgy 0 Active
US8603482B2 Compositions and methods for cancer immunotherapy Human Necessities 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.